Cidara Therapeutics Cultura da Companhia

Mr. Neil Abdollahian has been the Chief Business Officer of Cidara Therapeutics, Inc. since July 5, 2016. Mr. Abdollahian has over 16 years of corporate strategy, partnering and M&A experience in the biopharmaceutical industry and leads Cidara's business development strategy and execution. Prior to joining Cidara, Mr. Abdollahian served as Managing Director of the strategic advisory firm Clarity Point Partners and Mr. Onaitis was General Counsel and Secretary of Ignyta. From 2008 to 2013, he served as Vice President of Corporate Development at Trius Therapeutics, Inc. He also served as Senior Director for Business Development of Trius Therapeutics, Inc. Mr. Abdollahian began his career in the research sciences where his graduate research focused on neuronal energy metabolism. His experience in biopharmaceutical management includes more than 30 transactions ranging from early-stage technology collaborations, clinical-stage licensing transactions to acquisition and divestment of marketed therapeutics and companies. In 2008, Mr. Abdollahian was Director of Business Development & Special Projects at Emerging Growth Capital Pty. From 2001 to 2007, he spent years leading and closing high-value biotech transactions while at Avanir Pharmaceuticals, Isis Pharmaceuticals and Neurogen Corporation. He earned an MBA from Pepperdine University, an M.S. in the Biomedical Sciences from the University of New Mexico School of Medicine and a B.S. in the Biological Sciences from the George Washington University.

Dr. Kevin M. Forrest, Ph.D., Co-Founded Cidara Therapeutics, Inc. (K2 Therapeutics) since December 2012and has been its Chief Strategy Officer since July 1, 2016. Dr. Forrest served as the Chief Operating Officer and Chief Financial Officer from July 2014 to June , 2016 and February 2015 to June, 2016 respectively. Dr. Forrest served as Treasurer at Cidara Therapeutics, Inc. until July 1, 2016. He was a Principal at 5AM Venture Management LLC since February 20, 2008. He joined 5AM Ventures in 2005 as a Senior Associate. He also served as a Due Diligence Advisor at ProQuest Investments. Dr. Forrest serves on the board of VBI. He serves as a Member of the Board of Directors at VBI Vaccines Inc. He serves as a Board Observer of Ambrx, Biotech, Epirus and SteriCoat Inc. He served as a Board Observer of Relypsa, Inc., and Pulmatrix, Inc. Dr. Forrest previously represented 5AM as an Observer to Flexion, Marcadia Biotech, Inc, Semprus, Synosia and WaveRx, Inc. He served as a Director of Pulmatrix Inc. Dr. Forrest served as Director of Variation Biotechnologies, Inc. He served as a Director of EPIRUS Biopharmaceuticals, Inc. and Semprus BioSciences Corp. Dr. Forrest performed research on the genetics of human stuttering at the National Institute of Deafness and Other Communication Disorders. Dr. Forrest's research is published in Current Biology, Development and Developmental Cell. He was a Summer Fellow at the National Institutes of Health, where he studied the genetics of human stuttering. He holds a Ph.D. in Molecular Biology from Princeton University, where he studied RNA-based regulatory processes and a B.S. in Biology, with honors, from Boston College.

Mr. Marc J.C. Wilson serves as Principal Accounting Officer and Vice President of Finance & Accounting at Cidara Therapeutics, Inc. and served as its Director of Finance and Corporate Controller.

Mr. Matthew W. Onaitis, also known as Matt, J.D. has been the Chief Financial Officer, General Counsel and Secretary of Cidara Therapeutics, Inc. since July 1, 2016. Prior to joining Cidara, Mr. Onaitis served as a General Counsel and Secretary of Trius Therapeutics, Inc. from May 2013 to September 2013. Mr. Onaitis served as General Counsel and Secretary at Ignyta, Inc. since February 3, 2014 until May 31, 2016. Mr. Onaitis served as a Senior Vice President of Pernix Sleep, Inc. since April 1, 2010 and served as its General Counsel and Secretary since January 2007. Mr. Onaitis served as Vice President of Pernix Sleep, Inc. from January 2007 to April 1, 2010. He served as Vice President of legal affairs of Pernix Sleep, Inc. from May 2006 to January 2007 and Chief Legal Officer since May 2006. He served as an Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc., from January 2006 to May 2006. From June 2004 to December 2005, he served as Director of legal affairs for Elan Corporation, plc, where he was a Lead Transactional Counsel for the commercial operations and business development groups. Mr. Onaitis practiced corporate and commercial law at Clifford Chance LLP from July 2002 to June 2004, which included a secondment to Elan from October 2003 to June 2004. From April 2000 to July 2002, Mr. Onaitis practiced corporate and commercial law with the law firm of Brobeck, Phleger & Harrison LLP. Mr. Onaitis is a director of SNP Bio, Inc., a private biotechnology company. Mr. Onaitis has a Juris Doctorate degree from Stanford University and a Bachelor's of Science degree in Mechanical Engineering from Carnegie Mellon University.

James Levine serves as the CFO of Cidara Therapeutics. James started at Cidara Therapeutics in Dec of 2018. James currently resides in the Greater San Diego Area.

Jessica Oien serves as the Senior Vice President, General Counsel & Secretary of Cidara Therapeutics. Jessica started at Cidara Therapeutics in Sep of 2018. Jessica currently resides in the Greater San Diego Area.

Elizabeth Carbajal-DiVasto serves as the Vice President, Quality of Cidara Therapeutics. Elizabeth started at Cidara Therapeutics in Mar of 2017. Elizabeth currently resides in the Greater San Diego Area.

Ken Bartizal serves as the Chief Development Officer of Cidara Therapeutics. Ken started at Cidara Therapeutics in July of 2014. Ken currently resides in the Greater San Diego Area.